Výsledky vyhledávání - "Kaisa, Salmenkivi"

Akademický článek

PD-1 and PD-L1 expression in pulmonary carcinoid tumors and their association to tumor spread

Autor: Tiina Vesterinen, Teijo Kuopio, Maarit Ahtiainen, Aija Knuuttila, Harri Mustonen, Kaisa Salmenkivi, Johanna Arola, Caj Haglund

Publikováno v: Endocrine Connections, Vol 8, Iss 8, Pp 1168-1175 (2019)

Pulmonary carcinoid (PC) tumors are rare tumors that account for approximately 1% of all lung cancers. The primary treatment option is surgery, while there is no standard treatment for metastatic disease. As the number of PCs diagnosed yearly is incr

Externí odkaz: https://doaj.org/article/5b1ff3d49b504214a7d5c370ca7bc6d7

Zobrazit plný text záznamu

Akademický článek

CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure

Autor: Eeva Kettunen, Sauli Savukoski, Kaisa Salmenkivi, Tom Böhling, Esa Vanhala, Eeva Kuosma, Sisko Anttila, Henrik Wolff

Publikováno v: BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)

Abstract Background Deletion of the CDKN2A locus is centrally involved in the development of several malignancies. In malignant pleural mesothelioma (MPM), it is one of the most frequently reported genomic alteration. MPM is strongly associated with

Externí odkaz: https://doaj.org/article/131cca9545364481bce20e538437397f

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Cell of Origin Links Histotype Spectrum to Immune Microenvironment Diversity in Non-small-Cell Lung Cancer Driven by Mutant Kras and Loss of Lkb1

Autor: Ashwini S. Nagaraj, Jenni Lahtela, Annabrita Hemmes, Teijo Pellinen, Sami Blom, Jennifer R. Devlin, Kaisa Salmenkivi, Olli Kallioniemi, Mikko I. Mäyränpää, Katja Närhi, Emmy W. Verschuren

Publikováno v: Cell Reports, Vol 18, Iss 3, Pp 673-684 (2017)

Lung cancers exhibit pronounced functional heterogeneity, confounding precision medicine. We studied how the cell of origin contributes to phenotypic heterogeneity following conditional expression of KrasG12D and loss of Lkb1 (Kras;Lkb1). Using proge

Externí odkaz: https://doaj.org/article/4865c03d589649f090200e998d1e2cd4

Zobrazit plný text záznamu

Supplementary Table S1 from Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras-Mutant Lung Cancers

Autor: Emmy W. Verschuren, Krister Wennerberg, Mikko I. Mäyränpää, Kaisa Salmenkivi, Pipsa Saharinen, Elina A. Kiss, Swapnil Potdar, Annabrita Hemmes, Jennifer R. Devlin, Ashwini S. Nagaraj, Sarang S. Talwelkar

Table_S1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27859c01a5a1785161bc7a7bd455ec8a
https://doi.org/10.1158/1535-7163.22509207.v1

Zobrazit plný text záznamu

Supplementary Data from Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras-Mutant Lung Cancers

Supplementary text and figures

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25da8709577071f02aaeaf9cd8b88369
https://doi.org/10.1158/1535-7163.22509210.v1

Zobrazit plný text záznamu

Data from Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras-Mutant Lung Cancers

Most non–small cell lung cancers (NSCLC) contain nontargetable mutations, including KRAS, TP53, or STK11/LKB1 alterations. By coupling ex vivo drug sensitivity profiling with in vivo drug response studies, we aimed to identify drug vulnerabilities

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9d26d521c92c9d7c4073c63d907f5285
https://doi.org/10.1158/1535-7163.c.6539226.v1

Zobrazit plný text záznamu

SOX9 has distinct roles in the formation and progression of different non-small cell lung cancer histotypes

Autor: Mikko I. Mäyränpää, Emmy W. Verschuren, John Le Quesne, Ana Teodósio, Nora Linnavirta, Annabrita Hemmes, Kaisa Salmenkivi, Katja Närhi, Jie Bao

The transcription factor SOX9 is a key regulator of multiple developmental processes and is frequently re-expressed in non-small cell lung cancer (NSCLC). Its precise role in the progression of NSCLC histotypes has, however, remained elusive. We show

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b65e8f560d60ce3a7cba5a9afdb7268e
https://www.repository.cam.ac.uk/handle/1810/324129

Zobrazit plný text záznamu

Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras-Mutant Lung Cancers

Autor: Pipsa Saharinen, Swapnil Potdar, Jennifer R. Devlin, Emmy W. Verschuren, Elina A. Kiss, Kaisa Salmenkivi, Ashwini S. Nagaraj, Annabrita Hemmes, Krister Wennerberg, Sarang S. Talwelkar, Mikko I. Mäyränpää

Publikováno v: Talwelkar, S S, Nagaraj, A S, Devlin, J R, Hemmes, A, Potdar, S, Kiss, E A, Saharinen, P, Salmenkivi, K, Mäyränpää, M I, Wennerberg, K & Verschuren, E W 2019, ' Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras-Mutant Lung Cancers ', Molecular Cancer Therapeutics, vol. 18, no. 10, pp. 1863-1874 . https://doi.org/10.1158/1535-7163.MCT-18-0573

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e2218d9052825458be013ab20778337
https://doi.org/10.1158/1535-7163.mct-18-0573

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání